D3S-001

DB19008InvestigationalSmall molecule

D3S-001 is under investigation in clinical trial NCT05410145 (A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.g12c Mutation).

Mechanism: Pharmacologically active on GTPase KRas
Curator reviewed
Formula / weight: C₃₂H₃₅F₆N₇O₃ · 679.668 g/mol (avg)
Also known as: 2-PIPERAZINEACETONITRILE, 4-(7-(3-AMINO-2-FLUORO-5-METHYL-6-(TRIFLUOROMETHYL)PHENYL)-2-(((2R,7AS)-2-FLUOROTETRAHYDRO-1H-PYRROLIZIN-7A(5H)-YL)METHOXY)-7,8-DIHYDRO-5H-PYRANO(4,3-D)PYRIMIDIN-4-YL)-1-(2-FLUORO-1-OXO-2-PROPEN-1-YL)-, (2S)-
Code names: D3S-001

Resolves to

Compound

UNIIPFW9YLB86HCAS2706637-43-4

Structure

InChIKeyJOLORSRKBHXPFT-PNGHJTAWSA-NSMILESCC1=CC(N)=C(F)C([C@@H]2CC3=NC(OC[C@@]45CCCN4C[C@H](F)C5)=NC(N4CCN([C@@H](CC#N)C4)C(=O)C(F)=C)=C3CO2)=C1C(F)(F)F

Targets

P01116KRAS

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with D3S-001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account